Molecular Therapy Family of Journals (@moltherapy.bsky.social)

Growing clinical evidence for successful in vivo generation of CAR T cells directed against hematologic malignancies Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of B-cell malignancies and multiple myeloma (MM). Yet, its clinical success is limited by several logistical challenges such as patient-individualized manufacturing of CAR T cells, very long vein-to-vein time, high cost, and limited global access. Since the approval of CD19-and BCMA-targeted CAR T cells, the field has largely accepted laboratory-based cellular engineering as essential for achieving therapeutic potency. Starting last year, however, this status quo has been challenged by growing clinical evidence that a single infusion of CAR encoding vectors can substitute the complex ex vivo process. http://dlvr.it/TTbB3v